References:

1. Hunger SP, Lu, X., Devidas, M., Camitta, B.M., Gaynon, P.S., Winick, N.J.,, Reaman GH, Carroll, W.L. . Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children’s Oncology Group. Journal of Clinical Oncology. 2012;30(14):1663 - 1669.
2. Pui CH, Mullighan, C.G., Evans, W.E., Relling, M.V. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?Blood. 2012;120(6):1165-1174.
3. Gorman MF, Ji, L., Ko, R.H., Barnette, P., Bostrom, B., Hutchinson, R., Raetz, E., Seibel, N.L., Loh, M.L., et al. . Outcome for Children Treated for Relapsed or Refractory Acute Myelogenous Leukemia (rAML): A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Study.Pediatric Blood Cancer. 2010;55:421-429.
4. ALL- REZ BFM vS, A. (direcor of studies), Kretschmann, A. (Documentary). ALL-REZ BFM Beobachtungsstudie und Biobank für Rezidive einer akuten lymphoblastischen Leukämie im Kindes - und Jugendalter. version 20.09.2012.
5. Tallen G, Ratei, R., Mann, G., Kaspers, G., Niggli, F., Karachunsky, A., Ebell, W., Escherich, G., Schrappe, M., Klingebiel, T., Fengler, R., Henze, G. Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90. Journal of clinical oncology.2010;28 (14 ):2339 - 2347.
6. Bayraktar UD, Bashir, Q., Qazilbash, M., Champlin, R.E., Ciurea, S.O Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation.Biology of Blood and Marrow Transplantation. 2013;19:344e356.
7. Kato K, Yoshida, N., Matsumoto, K., Matsuyama, T. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor and Melphalan (FALG with L-PAM) as a Reduced Toxicity Conditioning Regimen in Children with Acute Leukemia. Pediatric Blood Cancer. 2014;61:712-716.
8. Oshrine B, Adams, L., Nguyen, A.T.H., Amankwah, E., Shyr, D., Hale, G., Petrovic, A. Comparison of melphalan- And busulfan-based myeloablative conditioning in children undergoing allogeneic transplantation for acute myeloid leukemia or myelodysplasia.Pediatric Transplantation. 2020:1 - 8.
9. Stentofi J. The Toxicity of Cytarabine. Drug Safety.1990;5:7-27.
10. AML-BFM-Study Group Coordination: Reinhardt D, Creutzig, U. International Registry Relapsed AML 2009 Registry of children and adolescents with relapsed or refractory acute myeloid leukemia (AML). 2009.
11. von Stackelberg A, Locatelli, F, Zugmaier, G., Handgretinger, R., Trippett, T.M., Rizzari, C., Bader ,P., O’Brien, M.M., Brethon, B., Bhojwani, D., Schlegel, P.G., Borkhardt, A., Rheingold, S.R., Cooper, T.M., Zwaan, C.M., Barnette, P., Messina, C., Michel, G., DuBois, S.G., Hu, K., Zhu, M., Whitlock, J.A., Gore, L. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. journal of Clinical Oncology.2016;34(36):4381 - 4389.
12. Gore L, Locatelli, F. Zugmaier, G., Handgretinger, R., O’Brien, M.M., Bader, P., Bhojwani, D., Schlegel, P.-G., Tuglus, C.A., von Stackelberg, A. Survival after blinatumomab treatment inpediatric patients with relapsed/refractoryB-cell precursor acute lymphoblasticleukemiaLia BloodCancerJournal. 2018;8(9).
13. Maude SL, Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M.R., Stefanski, H.E., Myers, G.D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K.L., Martin, P.L., Nemecek, E.R., Yanik, G.A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C.H., Levine, B.L., Wood, P., Taran, T., Leung, M., Mueller, K.T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M.A., Grupp, S.A. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine. 2018;378(5):439 - 448.
14. Abrahamsson J, Clausen, N., Gustafsson, G., Hovi, L., Jonmundsson, G., Zeller, B., Forestier, E., Heldrup, J., Hasle, H. . Improved outcome after relapse in children with acute myeloid Leukaemia. British journal of haematology. 2007;136:229-236.
15. Creutzig U. S, J., Kaspers, G.L., Reinhardt, D., Zimmermann, M. Re-induction with L-DNR/FLAG Improves Response after AML Relapse, but not Long-term Survival. Klinische Pädiatrie. 2014;226:323 - 331.
16. AIEOP-BFM study group. Coordinating principal investigator: Schrappe M. AIEOP-BFM ALL 2017: International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia: A randomized phase III study conducted by the AIEOP-BFM study group. Protocol version 1.5. EudraCT Number AIEOP-BFM ALL 2017: 2016-001935-12 2018.
17. Mustafa O, Abdalla, K., AlAzmi, A.A., Elimam, N., Abrar, M.B., Jastaniah, W. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies Journal of Oncology Pharmacy Practice. 2019;25(8):1831 - 1838.
18. Keshu Zhou YS, Yanli Zhang, Xudong Wei, Yuewen Fu, Fengkuan Yu, Hu Zhou, Xinjian Liu, Jian Zhou, Baijun Fang. Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with L-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia. Leukemia Research. 2017;62 29-33.
19. Steckel NK, Groth C., Mikesch, J.-H., Trenschel, R., Ottinger, H., Kordelas, L., Mueller‐Tidow, C., Schliemann, C., Reicherts, C. High‐dose melphalan‐based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. British journal of haematology. 2018;180(6):840 - 853.
20. Spitzer B, Perales, M.-A., Kernan, N.A., Prockop, S.E., Zabor, E.C., Webb, N., Castro-Malaspina, H., Papadopoulos, E.B., Young, J.W., Scaradavou, A., Kobos, R., Giralt, S.A., O’Reilly, R.J., Boulad, F. Second allogeneic stem cell transplantation for acute leukemia using a chemotherapy only cytoreduction with clofarabine, melphalan, and thiotepa. Biology of Blood and Marrow Transplantation.2016;22(8):1449 - 1454.
FIGURE 1: Overall survival rate of the whole cohort (n=8) after a salvage therapy with melphalan and cytarabine with a one year survival of 50% (n=4) and a three year survival of 29% (n=2)